Who owns Corvus Pharmaceuticals?
- Ticker: CRVS
- CUSIP Number: 221015100
Tip: Access positions for across all investors
Analyze quarterly positions in Corvus Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Corvus Pharmaceuticals stock
Who bought or sold Corvus Pharmaceuticals this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
OrbiMed Advisors | 6.9M | $37M | 0% | Sep 2024 |
|
Point72 Asset Management | 5.6M | $29M | -7% | Sep 2024 |
|
Samlyn Capital | 4.5M | $24M | -26% | Sep 2024 |
|
Vanguard Group | 1.7M | $3.0M | 11% | Jun 2024 |
|
BlackRock | 604k | $3.2M | 100% | Sep 2024 |
|
Geode Capital Management | 563k | $3.0M | 22% | Sep 2024 |
|
BlackRock | 562k | $1.0M | 7% | Jun 2024 |
|
Renaissance Technologies | 387k | $2.0M | -31% | Sep 2024 |
|
Morgan Stanley | 371k | $676k | 35% | Jun 2024 |
|
Schonfeld Strategic Advisors | 331k | $1.7M | 100% | Sep 2024 |
|
Marshall Wace | 323k | $1.7M | 333% | Sep 2024 |
|
Susquehanna International | 301k | $1.6M | 448% | Sep 2024 |
|
Ikarian Capital | 218k | $1.2M | 100% | Sep 2024 |
|
Citadel Advisors | 182k | $960k | 138% | Sep 2024 |
|
Connor, Clark & Lunn Investment Management | 137k | $724k | 65% | Sep 2024 |
|
Bridgeway Capital Management | 127k | $232k | -43% | Jun 2024 |
|
Citigroup | 123k | $649k | 100% | Sep 2024 |
|
State Street Corporation | 120k | $219k | 0% | Jun 2024 |
|
TowerView | 118k | $620k | -71% | Sep 2024 |
|
Two Sigma Advisers | 113k | $206k | -39% | Jun 2024 |
|
Northern Trust | 106k | $557k | 62% | Sep 2024 |
|
Acadian Asset Management | 80k | $420k | 100% | Sep 2024 |
|
Jackson Square Capital | 64k | $337k | 0% | Sep 2024 |
|
Jane Street | 50k | $265k | 100% | Sep 2024 |
|
Hikari Power | 50k | $264k | 0% | Sep 2024 |
|
Jpmorgan Chase & Co | 50k | $262k | 441% | Sep 2024 |
|
Two Sigma Investments | 48k | $87k | -53% | Jun 2024 |
|
Wolverine Trading | 42k | $214k | 100% | Sep 2024 |
|
Mission Wealth Management | 40k | $211k | 100% | Sep 2024 |
|
Gillespie Robinson & Grimm | 28k | $146k | 138% | Sep 2024 |
|
Ancora Advisors | 23k | $123k | 100% | Sep 2024 |
|
Quinn Opportunity Partners | 22k | $41k | 0% | Jun 2024 |
|
Commerce Bank N A | 20k | $106k | 0% | Sep 2024 |
|
American Century Companies | 18k | $96k | 0% | Sep 2024 |
|
Oppenheimer & Co | 17k | $90k | 100% | Sep 2024 |
|
Advisor Group Holdings | 17k | $88k | 1294% | Sep 2024 |
|
Virtu Financial | 16k | $83k | 100% | Sep 2024 |
|
Charles Schwab Investment Management | 16k | $83k | 0% | Sep 2024 |
|
Tower Research Capital | 15k | $28k | 33% | Jun 2024 |
|
Dimensional Fund Advisors | 12k | $63k | 0% | Sep 2024 |
|
Two Sigma Securities | 11k | $21k | 100% | Jun 2024 |
|
Whittier Trust Co. of Nevada | 11k | $59k | 0% | Sep 2024 |
|
Nwam | 10k | $53k | 100% | Sep 2024 |
|
Cubist Systematic Strategies | 10k | $53k | -59% | Sep 2024 |
|
Resources Investment Advisors | 10k | $53k | -31% | Sep 2024 |
|
Masso Torrence Wealth Management | 10k | $18k | 0% | Jun 2024 |
|
Rothschild Investment | 7.0k | $37k | 0% | Sep 2024 |
|
Simplex Trading | 5.7k | $29k | 156% | Sep 2024 |
|
Group One Trading | 5.6k | $29k | 100% | Sep 2024 |
|
Northwest Capital Management | 3.4k | $18k | 0% | Sep 2024 |
|
Bnp Paribas Arbitrage, Snc | 3.1k | $16k | 100% | Sep 2024 |
|
Western Pacific Wealth Management | 2.0k | $11k | 100% | Sep 2024 |
|
Rhumbline Advisers | 791.00 | $4.2k | 0% | Sep 2024 |
|
Bank of America Corporation | 409.00 | $2.2k | 4% | Sep 2024 |
|
IFP Advisors | 24.00 | $43.999200 | 0% | Jun 2024 |
|
Parallel Advisors | 20.00 | $106.000000 | 0% | Sep 2024 |
|
Barclays | 1.00 | $0 | 0% | Sep 2024 |
|
Who sold out of Corvus Pharmaceuticals?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Millennium Management | Jun 2024 | 205k | $372k |
Royal Bank of Canada | Jun 2024 | 7.2k | $17k |
Qube Research & Technologies | Mar 2024 | 2.4k | $4.2k |
ICA Group Wealth Management | Mar 2024 | 165.00 | $293.997000 |